Morning Recap: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) | Healthcare – The Daily Leicester

This post was originally published on this site

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) falls under the large cap category with a market cap of 47.31 B. The following data highlights Regeneron Pharmaceuticals, Inc. (REGN) for Thursday May 18, 2017 showing the earning date of 05/04/2017 8:30.

Overview

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a Biotechnology company from Healthcare sector has been doing very well. The company has reported a price of $446.72 today, marking a change of -1.77%.

Regeneron Pharmaceuticals, Inc. has a current return on equity (ROE) of 21.50% while its debt to equity stands at 0.15. The return on investment (ROI) is at 18.20% and the gross margin is reported to be 94.50%.

Regeneron Pharmaceuticals, Inc. is predicting a healthy earnings per share growth of 38.80% over the period of next five years.

Performance Analysis

The stats for Regeneron Pharmaceuticals, Inc.’s performance is below.

The weekly performance stands at 3.51%, while the monthly performance measure stands at 22.03%. Not surprisingly its volatility is at 2.86% with an average volume of 926.07. Volatility is a statistical measure of the dispersion of returns for a given security. It can be measured by using the variance between returns from the market index. Generally speaking, there is always a positive correlation between high volatility and high risk.

The performance per month is at 22.03%, while the performance per quarter stands at .

Ratio

has a float short of 3.89% at present and the short ratio is at 3.29. Shares shorted can actually exceed 50% of the float in a company. Because the float is the amount of a company’s shares that are publicly owned, all tradable shares can therefore be borrowed by short sellers.

Valuation

The numbers in regards to Regeneron Pharmaceuticals, Inc.’s valuation are below.

The market cap is at 47.31 B, while the P/E stands at 53.74, with a P/S of 9.5 and earnings per share this year of 39.50%.

The earnings per share is used as a primary indicator of a company’s profitability or loss. Earnings per share is basically the portion of a company’s profit that is allocated to each outstanding share of common stock.

Candle Graph for (NASDAQ: REGN)

REGN

Regeneron Pharmaceuticals, Inc. NASDAQ : REGN | Healthcare | Biotechnology

Disclaimer: The views, opinions, and information expressed in this article are those of the authors and will not necessarily reflect the official policy or position of any company stakeholders, financial professionals, or analysts.. Examples of analysis performed within this article are for demonstration purposes only. They should not be utilized to make stock portfolio or financial decisions as they are based on limited and open source information only. Hence the assumptions made within the analysis are not reflective of the position of any analysts or financial professionals.

This post was originally published on *this site*